source
- Rising oil prices could lift manufacturing costs of an HIV drug, Unitaid report saysRising oil prices, driven in part by geopolitical tensions, have raised concerns about the stability of medicine supply chains. Analysts note that higher energy costs can translate into increased p…
- FDA panel rejects Capricor's Duchenne drug, citing insufficient efficacy dataThe U.S. Food and Drug Administration advisory committee voted 9-to-3 against a Capricor Therapeutics candidate for Duchenne muscular dystrophy. The panel said the clinical data did not provide sub…